Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort

1Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet 2016; 387:1094-108. doi: 10.1016/S0140-6736(15)00130-0 Morice P Leary A Creutzberg C Abu-Rustum N Darai E Endometrial cancer Lancet 2016 3871094 108 10.1016/S0140-6736(15)00130-0Open DOISearch in Google Scholar

2Repše-Fokter A. Endometrial cancer in young woman. Acta Medico– Biotechnica 2020; 13: 60-4. Repše-Fokter A. Endometrial cancer in young woman Acta Medico– Biotechnica 2020 13 60 4Search in Google Scholar

3Zadnik V, Zagar T, Lokar K, Tomsic S, Konjevic AD, Zakotnik B. Trends in population-based cancer survival in Slovenia. Radiol Oncol 2021; 55: 42-9. doi: 10.2478/raon-2021-0003 Zadnik V Zagar T Lokar K Tomsic S Konjevic AD Zakotnik B Trends in population-based cancer survival in Slovenia Radiol Oncol 2021 55 42 9 10.2478/raon-2021-0003787726133885247Open DOISearch in Google Scholar

4Concin N, Matias-guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12-39. doi: 10.1136/ijgc-2020-002230 Concin N Matias-guiu X Vergote I Cibula D Mirza MR Marnitz S et al ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma Int J Gynecol Cancer 2021 31 12 39 10.1136/ijgc-2020-00223033397713Open DOISearch in Google Scholar

5Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer 2019; 19: 510-21. doi: 10.1038/s41568-019-0177-x Urick ME Bell DW Clinical actionability of molecular targets in endometrial cancer Nat Rev Cancer 2019 19 510 21 10.1038/s41568-019-0177-x744624331388127Open DOISearch in Google Scholar

6Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73. doi: 10.1038/nature12113 Cancer Genome Atlas Research Network Kandoth C Schultz N et al Integrated genomic characterization of endometrial carcinoma Nature 2013 497 67 73 10.1038/nature12113370473023636398Open DOISearch in Google Scholar

7Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 2018; 119: 1067-74. doi: 10.1038/s41416-018-0310-8 Wortman BG Creutzberg CL Putter H Jürgenliemk-Schulz IM Jobsen JJ Lutgens LCHW et al Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy Br J Cancer 2018 119 1067 74 10.1038/s41416-018-0310-8621949530356126Open DOISearch in Google Scholar

8McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. Cancer 2021; 26: 5400-10. doi: 10.1002/cncr.33516 McAlpine JN Chiu DS Nout RA Church DN Schmidt P Lam S et al Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis Cancer 2021 26 5400 10 10.1002/cncr.3351633793971Open DOISearch in Google Scholar

9Vermij L, Smit V, Nout R, Bosse T. Incorporation of molecular characteristics into endometrial cancer management. Histopathology 2020; 76: 52-63. doi: 10.1111/his.14015 Vermij L Smit V Nout R Bosse T Incorporation of molecular characteristics into endometrial cancer management Histopathology 2020 76 52 63 10.1111/his.14015697255831846532Open DOISearch in Google Scholar

10Abdulfatah E, Wakeling E, Sakr S, Al-Obaidy K, Bandyopadhyay S, Morris R, et al. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management. Gynecol Oncol 2019; 154: 467-74. doi: 10.1016/j.ygyno.2019.06.012 Abdulfatah E Wakeling E Sakr S Al-Obaidy K Bandyopadhyay S Morris R et al Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management Gynecol Oncol 2019 154 467 74 10.1016/j.ygyno.2019.06.01231248668Open DOISearch in Google Scholar

11Malentacchi F, Turrini I, Sorbi F, Projetto E, Castiglione F, Vergoni F, et al. Identification of a gene panel for endometrioid endometrial cancer: a possible prognostic value? Reprod Sci 2020; 27: 592-8. doi: 10.1007/s43032-019-00059-8 Malentacchi F Turrini I Sorbi F Projetto E Castiglione F Vergoni F et al Identification of a gene panel for endometrioid endometrial cancer: a possible prognostic value? Reprod Sci 2020 27 592 8 10.1007/s43032-019-00059-832046431Open DOISearch in Google Scholar

12McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538-49. doi: 10.1002/path.5034 McAlpine J Leon-Castillo A Bosse T The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses J Pathol 2018 244 538 49 10.1002/path.503429344951Open DOISearch in Google Scholar

13Raffone A, Travaglino A, Cerbone M, Guida M, Insabato L, Zannoni GF, et al. Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer. Pathol Oncol Res 2020; 26: 1417-27. doi: 10.1007/s12253-020-00811-5 Raffone A Travaglino A Cerbone M Guida M Insabato L Zannoni GF et al Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer Pathol Oncol Res 2020 26 1417 27 10.1007/s12253-020-00811-532377987Open DOISearch in Google Scholar

14Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 immunohistochemistry in endometrial carcinomas. Int J Gynecol Pathol 2019; 38: S123-S131. doi: 10.1097/PGP.0000000000000488 Köbel M Ronnett BM Singh N Soslow RA Gilks CB McCluggage WG Interpretation of P53 immunohistochemistry in endometrial carcinomas Int J Gynecol Pathol 2019 38 S123 S131 10.1097/PGP.0000000000000488612700529517499Open DOISearch in Google Scholar

15Ayhan A, Şahin H, Sari ME, Yalçin I, Haberal A, Meydanli MM. Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer. Int J Gynecol Cancer 2019; 29: 505-12. doi: 10.1136/ijgc-2018-000069 Ayhan A Şahin H Sari ME Yalçin I Haberal A Meydanli MM Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer Int J Gynecol Cancer 2019 29 505 12 10.1136/ijgc-2018-00006930665899Open DOISearch in Google Scholar

16Oberndorfer F, Moling S, Hagelkruys LA, Grimm C, Polterauer S, Sturdza A, et al. Risk reclassification of patients with endometrial cancer based on tumor molecular profiling: First real world data. J Pers Med 2021; 11: 1-11. doi: 10.3390/jpm11010048 Oberndorfer F Moling S Hagelkruys LA Grimm C Polterauer S Sturdza A et al Risk reclassification of patients with endometrial cancer based on tumor molecular profiling: First real world data J Pers Med 2021 11 1 11 10.3390/jpm11010048783051133467460Open DOISearch in Google Scholar

17Colombo N, Creutzberg C, Amant F, Cibula D, Mirza MR, Marnitz S, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer. Int J Gynecol Cancer 2016; 26: 2-30. doi: 10.1097/igc.0000000000000609 Colombo N Creutzberg C Amant F Cibula D Mirza MR Marnitz S et al ESMO-ESGO-ESTRO consensus conference on endometrial cancer Int J Gynecol Cancer 2016 26 2 30 10.1097/igc.0000000000000609467934426645990Open DOISearch in Google Scholar

18Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol 2013; 26: 1594-604. doi: 10.1038/modpathol.2013.102 Han G Sidhu D Duggan MA Arseneau J Cesari M Clement PB et al Reproducibility of histological cell type in high-grade endometrial carcinoma Mod Pathol 2013 26 1594 604 10.1038/modpathol.2013.10223807777Open DOISearch in Google Scholar

19Sobočan M, Ogrizek AM, Ledinek T, Takač I, Knez J. Importance of preoperative ultrasound examination and pathological tumour evaluation in the management of women with endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2021; 257: 121-126. doi: 10.1016/j.ejogrb.2020.12.029 Sobočan M Ogrizek AM Ledinek T Takač I Knez J Importance of preoperative ultrasound examination and pathological tumour evaluation in the management of women with endometrial cancer Eur J Obstet Gynecol Reprod Biol 2021 257 121 126 10.1016/j.ejogrb.2020.12.02933383411Open DOISearch in Google Scholar

20Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, et al. Uterine serous carcinoma. Gynecol Oncol 2021; 162: 226-34. doi: 10.1016/j.ygyno.2021.04.029 Bogani G Ray-Coquard I Concin N Ngoi NYL Morice P Enomoto T et al Uterine serous carcinoma Gynecol Oncol 2021 162 226 34 10.1016/j.ygyno.2021.04.02933934848Open DOISearch in Google Scholar

21Van Den Heerik ASVM, Horeweg N, De Boer SM, Bosse T, Creutzberg CL. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. Int J Gynecol Cancer 2021; 31: 594-604. doi: 10.1136/ijgc-2020-001822 Van Den Heerik ASVM Horeweg N De Boer SM Bosse T Creutzberg CL Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy Int J Gynecol Cancer 2021 31 594 604 10.1136/ijgc-2020-001822802008233082238Open DOISearch in Google Scholar

22Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015; 113: 299-310. doi: 10.1038/bjc.2015.190 Talhouk A McConechy MK Leung S Li-Chang HH Kwon JS Melnyk N et al A clinically applicable molecular-based classification for endometrial cancers Br J Cancer 2015 113 299 310 10.1038/bjc.2015.190450638126172027Open DOISearch in Google Scholar

23Kommoss FKF, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, et al. L1cam further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer 2018; 119: 480-6. doi: 10.1038/s41416-018-0187-6 Kommoss FKF Karnezis AN Kommoss F Talhouk A Taran FA Staebler A et al L1cam further stratifies endometrial carcinoma patients with no specific molecular risk profile Br J Cancer 2018 119 480 6 10.1038/s41416-018-0187-6613407630050154Open DOISearch in Google Scholar

24Weinberger V, Bednarikova M, Hausnerova J, Ovesna P, Vinklerova P, Minar L, et al. A novel approach to preoperative risk stratification in endometrial cancer: The added value of immunohistochemical markers. Front Oncol 2019; 9: 1-13. doi: 10.3389/fonc.2019.00265 Weinberger V Bednarikova M Hausnerova J Ovesna P Vinklerova P Minar L et al A novel approach to preoperative risk stratification in endometrial cancer: The added value of immunohistochemical markers Front Oncol 2019 9 1 13 10.3389/fonc.2019.00265647339431032226Open DOISearch in Google Scholar

25Imboden S, Tapia C, Scheiwiller N, Kocbek V, Altermatt HJ, Janzen J et al. Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence. Acta Obstet Gynecol Scand 2020; 99: 196-203. doi: 10.1111/aogs.13740 Imboden S Tapia C Scheiwiller N Kocbek V Altermatt HJ Janzen J et al Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence Acta Obstet Gynecol Scand 2020 99 196 203 10.1111/aogs.1374031562818Open DOISearch in Google Scholar

26Kolehmainen A, Pasanen A, Tuomi T, Koivisto-Korander R, Butzow R, Loukovaara M. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. PLoS One 2020; 15:1-12. doi: 10.1371/journal.pone.0242733 Kolehmainen A Pasanen A Tuomi T Koivisto-Korander R Butzow R Loukovaara M Clinical factors as prognostic variables among molecular subgroups of endometrial cancer PLoS One 2020 151 12 10.1371/journal.pone.0242733768542533232359Open DOISearch in Google Scholar

27León-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol 2020; 250: 312-22. doi: 10.1002/path.5373 León-Castillo A Gilvazquez E Nout R Smit VT McAlpine JN McConechy M et al Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas J Pathol 2020 250 312 22 10.1002/path.5373706518431829447Open DOISearch in Google Scholar

28Leon-Castillo A, De Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020; 38: 3388-97. doi: 10.1200/JCO.20.00549 Leon-Castillo A De Boer SM Powell ME Mileshkin LR Mackay HJ Leary A et al Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy J Clin Oncol 2020 38 3388 97 10.1200/JCO.20.00549752715632749941Open DOISearch in Google Scholar